Abstract
Widespread resistance of Plasmodium falciparum to chloroquine and sulfadoxinepyrimethamine has prompted the federal government of Nigeria, in line with WHO recommendations to adopt artemisinin-based combinations as first-line treatment of acute uncomplicated Plasmodium falciparum malaria. We evaluated 3 artemisinin-based combinations available in the Nigerian market to determine their efficacy and tolerability. Adequate clinical and parasitological response (ACPR) was comparable between artemetherlumefantrine (A-L) and artesunate-amodiaquine (AS-AQ) groups (92.8% v 91.2%, p = 0.79), both combinations being significantly more efficacious than artesunate-sulfadoxinepyrimethamine (AS-SP) group (A-L v AS-SP 92.8% v 69%; p = 0.005); (AS-AQ v AS-SP 91.2% v 69%; p = 0.018). Drug-related adverse events were significantly higher among the AS-AQ group compared to other treatment combinations (p = 0.004). We conclude that A-L and ASAQ have high comparative cure rates among patients evaluated in ilorin, Nigeria. Tolerability concern should play an important consideration when prescribing AS-AQ especially among adult patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.